High expression of ERBB3 in certain human cancers led early to the suggestion that it could be a therapeutic target (25–28), but in some cancer cells the mesenchymal phenotype was found to lose ERBB3 expression and show resistance to EGFR inhibitors. Here, ERBB3 is linked to cancer.